GKOS - Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst | Benzinga
Thursday, Glaukos Corporation (NYSE:GKOS) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the consensus of $(0.57).
The company reported sales of $85.6 million, up 16% Y/Y, beating the consensus of $79.6 million.
Guidance: Glaukos expects 2024 sales of $357 million-$365 million, compared to the consensus of $357.934 million.
William Blair reports that iDose exceeded expectations during its initial quarter of launch, with the iStent franchise experiencing growth in the mid-teens, surpassing expectations as well. The growth was driven by the demand for the iStent infinite product, which not only contributed to market expansion but also captured market share in the core combo-cataract segment.
“Clearly, the glaucoma business is firing on all cylinders, and ...